Article Details

Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic ...

Retrieved on: 2021-08-16 12:56:15

Tags for this article:

Click the tags to see associated articles and topics

Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic .... View article details on hiswai:

Excerpt

mRNA-3705 is Moderna's second rare disease program to enter clinical studies. mRNA-3705 granted Orphan Drug and Rare Pediatric Disease ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up